Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 5.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.55 | 2.22 |
NAV | ₹428.64 | ₹95.23 |
Fund Started | 09 Jul 2004 | 25 Mar 1997 |
Fund Size | ₹48307.68 Cr | ₹1084.99 Cr |
Exit Load | Exit load of 1% if redeemed within 12 months | Exit load of 1%, if redeemed within 30 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 14.74% | 10.58% |
3 Year | 18.86% | 20.01% |
5 Year | 24.20% | 22.24% |
1 Year
3 Year
5 Year
Equity | 90.30% | 99.31% |
Cash | 3.80% | 0.69% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
HDFC Bank Ltd. | 8.17% |
ICICI Bank Ltd. | 6.76% |
Reliance Industries Ltd. | 6.27% |
Infosys Ltd. | 5.51% |
Sun Pharmaceutical Industries Ltd. | 4.92% |
Axis Bank Ltd. | 3.75% |
Maruti Suzuki India Ltd. | 3.64% |
State Bank of India | 3.19% |
Hindustan Unilever Ltd. | 3.11% |
Bharti Airtel Ltd. | 3.09% |
Name | Assets |
---|---|
HDFC Bank Ltd. | 7.21% |
Infosys Ltd. | 4.57% |
ICICI Bank Ltd. | 4.12% |
Dr. Reddy's Laboratories Ltd. | 3.14% |
State Bank of India | 2.74% |
NTPC Ltd. | 2.64% |
REC Ltd. | 2.49% |
Tech Mahindra Ltd. | 2.23% |
Amber Enterprises India Ltd. | 2.16% |
Suven Pharmaceuticals Ltd. | 2.07% |
Name | Sankaran Naren | Satish Ramanathan |
Start Date | 27 Dec 2021 | 01 Oct 2024 |
Name
Start Date
Description | The scheme seeks to generate returns through a combination of dividend income and capital appreciation by investing primarily in a well-diversified portfolio of value stocks. | The scheme aims to provide long term capital growth by investing primarily in a well-diversified portfolio of undervalued securities. |
Launch Date | 09 Jul 2004 | 25 Mar 1997 |
Description
Launch Date